Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Creo Medical reveals double-first success for Speedboat endoscopic advanced energy device

Speedboat is the first device developed for use with the Welsh company's CROMA generator, which allows doctors to carry out surgical procedures without the need to puncture the skin
Hospital operation
Until now, the device has only been used in a clinical setting in the United Kingdom for lower gastrointestinal procedures

Creo Medical Group PLC (LON:CRO) jumped higher on Thursday after the medical device company announced the successful first use of its Speedboat endoscopic advanced energy device in seven upper gastrointestinal (GI) tract patients in South Africa.

Speedboat is the first device developed for use with the Welsh company's CROMA generator, which allows doctors to carry out surgical procedures without the need to puncture the skin.

READ: Two huge licensing deals help Oxford BioMedica swing to a first-half profit

CROMA is an electrosurgical platform that combines bipolar radiofrequency for precise, localised cutting and microwave technology for controlled coagulation.

The AIM-listed group said Speedboat harnesses the cut and coagulation of the generator to enable the removal of cancerous and pre-cancerous GI growths.

Until now, the device has only been used in a clinical setting in the United Kingdom for lower gastrointestinal procedures.

Craig Gulliford, Creo's chief executive officer, said: "This is a double first for Creo. The use of our lead product, Speedboat, in upper GI procedures and in a clinical setting outside of the UK is a key step in the commercialisation of our technology.”

In early afternoon trading, Creo Medical shares were up 13% at  189.5p.

View full CREO profile View Profile

Creo Medical Group PLC Timeline

Newswire
December 06 2016

Related Articles

1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
cancer
July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use